Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials
Zinman B, Verma S, Bain SC, Honore JB, Mann J, Nauck MA, Pratley R, Rasmussen S, Ripa MS, Buse JB (2019)
Publication Type: Conference contribution
Publication year: 2019
Journal
Publisher: SPRINGER
City/Town: NEW YORK
Pages Range: S365-S366
Conference Proceedings Title: DIABETOLOGIA
Event location: Barcelona
DOI: 10.1016/j.cjca.2019.07.568
Involved external institutions
Novo Nordisk A/S
Denmark (DK)
AdventHealth
United States (USA) (US)
St. Michael's Hospital
Canada (CA)
Swansea University
United Kingdom (GB)
University of North Carolina at Chapel Hill
United States (USA) (US)
University of Toronto
Canada (CA)
Ruhr-Universität Bochum (RUB)
Germany (DE)
Denmark (DK)
AdventHealth
United States (USA) (US)
St. Michael's Hospital
Canada (CA)
Swansea University
United Kingdom (GB)
University of North Carolina at Chapel Hill
United States (USA) (US)
University of Toronto
Canada (CA)
Ruhr-Universität Bochum (RUB)
Germany (DE)
How to cite
APA:
Zinman, B., Verma, S., Bain, S.C., Honore, J.B., Mann, J., Nauck, M.A.,... Buse, J.B. (2019). Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials. In DIABETOLOGIA (pp. S365-S366). Barcelona, ES: NEW YORK: SPRINGER.
MLA:
Zinman, B., et al. "Impact of microvascular disease on cardiorenal outcomes in type 2 diabetes: an analysis from the LEADER and SUSTAIN 6 clinical trials." Proceedings of the 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Barcelona NEW YORK: SPRINGER, 2019. S365-S366.
BibTeX: Download